CSF2 and colonic neoplasm: A modified NDV engineered to encode TRAIL (NDV-TRAIL) exhibited increased apoptotic activity in colon cancer cells compared to wild-type NDV [33], while GM-CSF-expressing NDV drove robust oncolytic effects and durable systemic antitumor immunity in both human tumor cells and three syngeneic in vivo models [34].